Daniel Chevallard
Director of Finance/CFO at Viracta Subsidiary, Inc.
Net worth: 104 352 $ as of 31/03/2024
Profile
Daniel R.
Chevallard is currently the Chief Financial Officer at Viracta Subsidiary, Inc. since 2019 and at LENZ Therapeutics, Inc. since 2024.
Previously, he worked as the Controller & Senior Director-Finance at Prometheus Laboratories, Inc. and as the Chief Financial Officer & Secretary at Sunesis Pharmaceuticals, Inc. From 2017 to 2019, he served as the Chief Financial & Accounting Officer at Regulus Therapeutics, Inc. He also held the position of Secretary, Chief Operating & Financial Officer at Viracta Therapeutics, Inc. from 2021 to 2024.
Mr. Chevallard completed his undergraduate degree at the University of San Diego.
Known holdings in public companies
Company | Date | Number of shares | Valuation | Valuation date |
---|---|---|---|---|
12/03/2024 | 102,306 ( 0.26% ) | 104 352 $ | 31/03/2024 |
Daniel Chevallard active positions
Companies | Position | Start |
---|---|---|
Viracta Subsidiary, Inc.
Viracta Subsidiary, Inc. BiotechnologyHealth Technology Viracta Subsidiary, Inc. engages in the development of proprietary viral gene activation therapy to address cancers associated with the Epstein-Barr virus. Its platform is designed as a targeted approach to treat a range of viral-associated cancers and other serious diseases. The company was founded by Ronald J. Berenson, Douglas V. Faller, George C. Hillman, Thalia Papayannopoulou, Susan P. Perrine, George Stamatoyannopoulos, and Robert Williams and is headquartered in Cardiff, CA. | Director of Finance/CFO | 01/07/2019 |
Former positions of Daniel Chevallard
Companies | Position | End |
---|---|---|
VIRACTA THERAPEUTICS, INC. | Director of Finance/CFO | 20/03/2024 |
REGULUS THERAPEUTICS INC. | Director of Finance/CFO | 26/07/2019 |
VIRACTA THERAPEUTICS, INC. | Director of Finance/CFO | - |
Prometheus Laboratories, Inc.
Prometheus Laboratories, Inc. Pharmaceuticals: MajorHealth Technology Prometheus Laboratories, Inc. develops and commercializes novel pharmaceutical and diagnostic products. Its enables physicians to provide individualized patient care. It applies the principles of personalized medicine to the diagnosis and treatment of gastrointestinal diseases and applies it to oncology. The firms markets and promotes pharmaceutical products and complementary proprietary diagnostic testing services. The company was founded by Jonathan Braun, Stephan R. Targan, Michael J. Walsh, and Scott L. Glenn in 1995 and is headquartered in San Diego, CA. | Director of Finance/CFO | - |
Training of Daniel Chevallard
University of San Diego | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 2 |
---|---|
REGULUS THERAPEUTICS INC. | Health Technology |
VIRACTA THERAPEUTICS, INC. | Health Technology |
Private companies | 3 |
---|---|
Sunesis Pharmaceuticals, Inc.
Sunesis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sunesis Pharmaceuticals, Inc. engages in the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. The firm's activities include conducting research and development internally and through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, conducting clinical trials and raising capital. The company was founded on February 10, 1998 and is headquartered in South San Francisco, CA. | Health Technology |
Prometheus Laboratories, Inc.
Prometheus Laboratories, Inc. Pharmaceuticals: MajorHealth Technology Prometheus Laboratories, Inc. develops and commercializes novel pharmaceutical and diagnostic products. Its enables physicians to provide individualized patient care. It applies the principles of personalized medicine to the diagnosis and treatment of gastrointestinal diseases and applies it to oncology. The firms markets and promotes pharmaceutical products and complementary proprietary diagnostic testing services. The company was founded by Jonathan Braun, Stephan R. Targan, Michael J. Walsh, and Scott L. Glenn in 1995 and is headquartered in San Diego, CA. | Health Technology |
Viracta Subsidiary, Inc.
Viracta Subsidiary, Inc. BiotechnologyHealth Technology Viracta Subsidiary, Inc. engages in the development of proprietary viral gene activation therapy to address cancers associated with the Epstein-Barr virus. Its platform is designed as a targeted approach to treat a range of viral-associated cancers and other serious diseases. The company was founded by Ronald J. Berenson, Douglas V. Faller, George C. Hillman, Thalia Papayannopoulou, Susan P. Perrine, George Stamatoyannopoulos, and Robert Williams and is headquartered in Cardiff, CA. | Health Technology |
- Stock Market
- Insiders
- Daniel Chevallard